Artiva Biotherapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Artiva Biotherapeutics, Inc. (ARTV) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $783.00K, a 72.66% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$2.63M, a 451.07% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.89M.
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$194.00K, a 112.92% decline year-over-year.
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.53M, a 21.93% decline from fiscal 2024.
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.97M.
- Artiva Biotherapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$516.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $783.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.85M 10-Q · filed 2026-08-06 | -$3.74M derived: sum of 3 quarters · filed 2026-08-06 | -$3.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$2.63M 10-Q · filed 2026-05-08 | -$4.52M derived: sum of 2 quarters · filed 2026-05-08 | -$4.71M derived: sum of 3 quarters · filed 2026-05-08 | -$1.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$2.08M derived: sum of 2 quarters · filed 2026-03-10 | $784.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.53M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$194.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.67M derived: sum of 2 quarters · filed 2026-08-06 | $3.42M 10-Q · filed 2025-11-12 | $3.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.61M 10-Q · filed 2026-08-06 | $3.44M derived: sum of 3 quarters · filed 2026-08-06 | $4.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $750.00K 10-Q · filed 2026-05-08 | $574.00K derived: sum of 2 quarters · filed 2026-05-08 | $2.08M derived: sum of 3 quarters · filed 2026-05-08 | $1.78M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.32M derived: sum of 2 quarters · filed 2026-03-10 | $1.03M derived: sum of 3 quarters · filed 2026-03-10 | $1.97M 10-K · filed 2026-03-10 |
| 2024-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.21M derived: sum of 2 quarters · filed 2025-11-12 | $2.14M 10-Q · filed 2025-11-12 | $1.92M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $640.00K 10-Q · filed 2025-08-06 | $422.00K derived: sum of 3 quarters · filed 2025-08-06 | $1.19M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $936.00K 10-Q · filed 2025-05-08 | $718.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.49M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $554.00K derived: sum of 2 quarters · filed 2025-03-24 | -$516.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $772.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$298.00K 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$1.07M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |